Clinical trial
A Phase 2 Study of Pegylated Recombinant Human Growth Hormone Injection to Treat Children of Turner Syndrome
NCT03189160 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Pegylated Recombinant Human Growth Hormone Injection to Treat Children of Turner Syndrome
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 31, 2016
- Completion date
- Not reported
- Enrollment
- 180 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.